Goldstein, D. A., Chen, Q., Howard, D. H., Lipscomb, J., Ayer, T., El-Rayes, B., & Flowers, C. R. (2014). Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line treatment of metastatic colorectal cancer (mCRC). Gastrointest Cancer Res.
Citação norma ChicagoGoldstein, Daniel A., Qiushi Chen, David H. Howard, Joseph Lipscomb, Turgay Ayer, Bassel El-Rayes, and Christopher R. Flowers. "Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line Treatment of Metastatic Colorectal Cancer (mCRC)." Gastrointest Cancer Res 2014.
Citação norma MLAGoldstein, Daniel A., et al. "Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line Treatment of Metastatic Colorectal Cancer (mCRC)." Gastrointest Cancer Res 2014.